<DOC>
	<DOC>NCT01428362</DOC>
	<brief_summary>The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.</brief_summary>
	<brief_title>VI-1121 for the Treatment Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>clinical diagnosis of Alzheimer's disease CT or MRI within 2 years prior to study stable dose of current Alzheimer's treatment for at least 3 months advanced, severe, progressive or unstable disease history of cerebrovascular disease or myocardial infarction within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>donepezil</keyword>
	<keyword>VI-1121</keyword>
</DOC>